Hengrui Pharmaceutical said at the 2026 semi-annual results briefing on September 10 that it is expected that more than 40 marketing applications will be approved from 2027 to 2028, covering 5 major treatment fields. Among them, potential major products include SHR-A2009, the first single-target HER3 ADC drug to be declared for marketing in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.